Abstract
Currently, the relevance of the issues of diagnosis and treatment of invasive fungal diseases has increased significantly due to the pandemic of a new coronavirus infection COVID-19 and the massive use of corticosteroids for the treatment. The key success factors in the outcome of invasive fungal diseases are early diagnosis and treatment, including the applying of an adequate systemic antifungal therapy and surgical treatment. Extensive areas of mycotic lesions of the facial bones and paranasal sinuses are lifethreatening conditions due to anatomical proximity to brain structures and a high risk of dissemination of I invasive fungal diseases with a fatal outcome. The objective of this work was to study the risk factors, possible pathogenesis, diagnosis and treatment strategy of invasive fungal diseases of the orofacial region in convalescents of COVID-19. We present case-series data on six patients in the clinics of maxillofacial surgery and otorhinolaryngology of the Pavlov First Saint Petersburg State Medical University over the period of 2021–2022. Predisposing factors, clinical and radiological symptoms, features of diagnosis, therapy and surgical strategy were analyzed. The presented observations confirm the relevance and danger of complications after a COVID-19 in the form of the development of invasive fungal diseases with damage to the maxillofacial region caused by mucormycetes and Aspergillus spp., as well as importance of early diagnosis and treatment.
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Pavlov First Saint Petersburg State Medical University, Saint-Petersburg, Russia
Raisa Gorbacheva Memorial Research Institute of Pediatric Oncology, Hematology and Transplantation, Saint-Petersburg, Russia
North-Western State Medical University named after I.I. Mechnikov, Saint-Petersburg, Russia
-
1.
Ambereen A., Rahman S., Rehman S., Zaidi K., Arif S.H. Mandibular mucormycosis following SARS-CoV-2 infection – a case report and review of literature. Clin Infect Pract. 2021;12:100099.
DOI: 10.1016/j.clinpr.2021.100099
-
2.
Boymuradov S.A., Rustamova D.A., Bobamuratova D.T., Kurbanov Y.X., Karimberdiyev Sh., Yusupov R., et al. Complications of COVID-19 in the maxillofacial region: clinical case and review of the literature. Advances in Oral and Maxillofacial Surgery. 2021;3:100091.
DOI: 10.1016/j.adoms.2021.100091
-
3.
Prakash H., Chakrabarti A. Global epidemiology of mucormycosis. J Fungi. 2019;5(1):26.
DOI: 10.3390/jof5010026
-
4.
Cornely O.A., Alastruey-Izquierdo A., Arenz D., Chen S.C.A., Dannaoui E., Hochhegger B., et al. Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium. Lancet Infect Dis. 2019;19(12):405-421.
DOI: 10.1016/S14733099(19)30312-3
-
5.
Rogacheva Y.A., Popova M.O., Markova I.V., Volkova A.G., Ekushev K.A., Paina O.V., et al. Invasive mycoses caused by rare pathogens in children with malignant tumors and non-malignant diseases of hematopoietic and lymphatic tissue after bone marrow transplantation and antineoplastic chemotherapy. Pediatrija. 2019;98(1):2835. Russian.
DOI: 10.24110/0031-403X-201998-1-28-35
-
6.
Hammond S.P., Baden L.R., Marty F.M. Mortality in hematologic malignancy and hematopoietic stem cell transplant patients with mucormycosis, 2001 to 2009. Antimicrob Agents Chemother. 2011;55(11):5018-5021.
DOI: 10.1128/AAC.00536-11
-
7.
Zilberberg M.D., Shorr A.F., Huang H. Chaudhari P., Paly V.F., Menzin J. Hospital days, hospitalization costs, and inpatient mortality among patients with mucormycosis: a retrospective analysis of US hospital discharge data. BMC Infect Dis. 2014;14(2):310.
DOI: 10.1186/1471-233414-310
-
8.
Jeong W., Keighley C., Wolfe R., Lee W.L., Slavin M.A., Kong D.C.M., Chen S.C. The epidemiology and clinical manifestations of mucormycosis: a systematic review and meta-analysis of case reports. Clin Microbiol Infect. 2019;25(1):26-34.
DOI: 10.1016/j.cmi.2018.07.011
-
9.
Klimko N., Khostelidi S., Shadrivova O., Volkova A., Popova M., Uspenskaya O., et al. Contrasts between mucormycosis and aspergillosis in oncohematological patients. Med Mycol. 2019;57(Suppl. 2):S138-S144.
DOI: 10.1093/mmy/myy116
-
10.
Klimko N.N., Khostelidi S.N., Shadrivova O.V., Bogomolova T.S., Avdeenko Y.L., Volkova A.G., et al. Mucormycosis in oncohematology patients (results of the prospective study). Oncohematology. 2017;12(2):14-22. Russian.
DOI: 10.17650/1818-8346-2017-12-2-14-22
-
11.
Rudramurthy S.M., Hoenigl M., Meis J.F., Cornely O.A., Muthu V., Gangneux J.P., et al. ECMM/ISHAM recommendations for clinical management of COVID-19 associated mucormycosis in low-and middle-income countries. Mycoses. 2021;64(9):1028-1037.
DOI: 10.1111/myc.13335
-
12.
Selarka L., Sharma S., Saini D., Sharma S., Batra A., Waghmare V.T., et al. Mucormycosis and COVID-19: an epidemic within a pandemic in India. Mycoses. 2021;64(10):1253-1260.
DOI: 10.1111/myc.13353
-
13.
Singh A.K., Singh R., Joshi S.R., Misra A. Mucormycosis in COVID-19: a systematic review of cases reported worldwide and in India. Diabetes Metab Syndr. 2021;15(4):102146.
DOI: 10.1016/j.dsx.2021.05.019
-
14.
John T.M., Jacob C.N., Kontoyiannis D.P. When uncontrolled diabetes mellitus and severe COVID-19 converge: the perfect storm for mucormycosis. J Fungi (Basel). 2021;7(4):298.
DOI: 10.3390/jof7040298
-
15.
Al-Tawfiq J.A., Alhumaid S., Alshukairi A.N., Temsah M.-H., Barry M., Mutair A.A., et al. COVID-19 and mucormycosis superinfection: the perfect storm. Infection. 2021;49(5):833-853.
DOI: 10.1007/s15010-02101670-1
-
16.
Rao V.U.S., Arakeri G., Madikeri G., Shan A., Oeppen R.S., Brennan P.A. COVID-19 associated mucormycosis (CAM) in India: a formidable challenge. Br J Oral Maxillofac Surg. 2021;59(9):1095-1098.
DOI: 10.1016/j.bjoms.2021.06.013
-
17.
Mehta S., Pandey A. Rhino-orbital mucormycosis associated with COVID-19. Cureus. 2020;12(9):e10726.
DOI: 10.7759/cureus.10726
-
18.
Deek A.J., Boukovalas S., Rathfoot C.J., Gotcher J.E. Rhinocerebral mucormycosis as a sequelae of COVID-19 treatment: a case report & literature Review. J Oral Maxillofac Surg. 2022;80(2):333-340.
DOI: 10.1016/j.joms.2021.09.009
-
19.
Donnelly J.P., Chen S.C., Kauffman C.A., Steinbach W.J., Baddley J.W., Verweij P.E., et al. Revision and update of the consensus definitions of invasive fungal disease from the European organization for research and treatment of cancer and the mycoses study group education and research consortium. Clin Infect Dis. 2020;71(6):1367-1376.
DOI: 10.1093/cid/ciz1008
-
20.
Temporary clinical recommendations «Prophylaxis, diagnostic and treatment new coronavirus infection COVID-19». Available at: https://static-0.minzdrav.gov.ru/system/attachments/attaches/000/058/392/original/ВМР13.1-from-17-11-2021.pdf. Accessed February 13, 2022. Russian.
-
21.
Sen M., Honavar S., Bansal R., Sengupta S., Rao R., Kim U., et al. Epidemiology, clinical profile, management, and outcome of COVID-19-associated rhino-orbital-cerebral mucormycosis in 2826 patients in India – collaborative OPAI-IJO study on mucormycosis in COVID-19 (COSMIC), Report 1. Indian J Ophthalmol. 2021;69(7):1670-1692.
DOI: 10.4103/ijo.IJO_1565_21
-
22.
Hoenigl M., Seidel D., Carvalho A., Rudramurty S.M., Arastehfar A., Gangneux J.-P., et al. The emergence of COVID-19 associated Mucormycosis: a review of cases from 18 countries. Lancet Microbe. 2022 Jan 25.
DOI: 10.1016/S2666-5247(21)00237-8